Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Buehlmann Laboratories AG maintains a presence in the Biotechnology & Pharmaceuticals technology area with 1 pending office action. This action is being processed by 1 distinct examiner, indicating that the company's current interactions with the patent office are highly centralized. The data shows that the portfolio is currently interacting with only 1 distinct art unit, which reflects a narrow technical focus for the pending applications. This structure implies that the applications are being evaluated within a single specialized division.
The busiest examiner for the portfolio is SAOUD, CHRISTINE J, who is currently handling the 1 pending office action. This single examiner's pending count of 1 matches the total number of pending actions for the company, meaning no other examiners are currently active. For practitioners, this highlights the importance of understanding the specific preferences and history of this examiner. The prosecution environment is streamlined, with all active matters consolidated under one individual in one specific art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAOUD, CHRISTINE J | 1 | 57.9% | +37.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801135 | Recombinant calprotectin | SAOUD, CHRISTINE J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17801135 | Recombinant calprotectin | SAOUD, CHRISTINE J | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17801135 | Recombinant calprotectin | SAOUD, CHRISTINE J | 1645 | §103§112 | Non-Final OA | — | Pending | Aug 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBuehlmann Laboratories AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Christine J Saoud has the most, with 1 of Buehlmann Laboratories AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
